No person-to-person spread has been detected, but that doesn’t mean an H5N1 avian influenza pandemic isn’t possible or even ...

The Agreement provides participating countries with the opportunity to diversify their mRNA COVID-19 vaccine supply and gain access to pre-filled ...

RNA vaccine developer Moderna (MRNA) is climbing nearly 5% in early trading today after it was awarded about $590 million by the U.S. government’s Department of Health and Human Services (HHS) on ...

The press release also contained forward-looking statements, cautioning that these are not guarantees and are subject to risks, uncertainties, and other factors that could cause actual results to ...

Kennedy Jr., a vocal vaccine skeptic ... HHS said its award to Moderna was, in part, to “enhance mRNA platform capabilities.” “The award made today is part of the ASPR’s commitment ...

The support is designed to speed development of well-matched H5N1 vaccines and pave the way for vaccines against other ...

Moderna, Inc. (NASDAQ:MRNA) today announced ongoing support from the U.S. Department of Health and Human Services (HHS) to accelerate the development of mRNA-based pandemic influenza vaccines. The ...

In this review of RNA therapies, we paint an overview of what’s going on in a field that is addressing a number of diseases.

As Moderna (NASDAQ: MRNA) looks to shore up its business in the wake of its declining coronavirus vaccine sales ... lot to prove about the value of its platform and its general competency in ...

Last Friday, HHS announced it will provide approximately $590 million to Moderna to accelerate the development of mRNA-based ...